Aptitude Medical Systems
Aptitude Medical Systems is a deep-tech healthcare company dedicated to democratizing diagnostics by creating simple, accurate, and easy-to-use molecular diagnostic platforms. Their mission is to make healthcare more accessible and affordable, enabling individuals to access their health information anytime, anywhere. Their flagship product, Metrix®, is an FDA-authorized molecular diagnostic platform that offers lab-quality results in minutes, suitable for use in various settings including urgent care centers, physician offices, hospitals, and homes. The company is actively involved in developing diagnostics for infectious diseases, including COVID-19 and sexually transmitted infections, with a focus on point-of-care and over-the-counter testing solutions.
Industries
Nr. of Employees
small (1-50)
Aptitude Medical Systems
125 Cremona Drive, Suite 100, Goleta CA, 93117
Patents
Compositions, methods and systems for identifying candidate nucleic acid agent
US-11248231-B2
View Details
Compositions, methods and systems for identifying candidate nucleic acid agent
US-11248231-B2
View DetailsProducts
Portable molecular diagnostic platform (reader and consumable assays)
A palm-sized diagnostic reader paired with disposable molecular test consumables designed to run rapid PCR-based assays in decentralized settings without user calibration or maintenance.
COVID-19 molecular test for decentralized and at-home use
A PCR-based molecular test intended for over-the-counter and point-of-care use with saliva and nasal swab samples; documented with Instructions for Use, quick reference guides, and provider fact sheets.
Respiratory multiplex test (COVID/Flu) and pipeline multiplex panels
Multiplex molecular assays in development to detect respiratory pathogens (e.g., SARS-CoV-2 and influenza) and additional syndromic panels for broader infectious disease testing.
Multiplex STI panel (development funded via philanthropic partnership)
Development program for a multiplex panel to detect sexually transmitted infections (CT, NG, TV) intended for point-of-care and over-the-counter use; program supported by external grant funding.
Portable molecular diagnostic platform (reader and consumable assays)
A palm-sized diagnostic reader paired with disposable molecular test consumables designed to run rapid PCR-based assays in decentralized settings without user calibration or maintenance.
COVID-19 molecular test for decentralized and at-home use
A PCR-based molecular test intended for over-the-counter and point-of-care use with saliva and nasal swab samples; documented with Instructions for Use, quick reference guides, and provider fact sheets.
Respiratory multiplex test (COVID/Flu) and pipeline multiplex panels
Multiplex molecular assays in development to detect respiratory pathogens (e.g., SARS-CoV-2 and influenza) and additional syndromic panels for broader infectious disease testing.
Multiplex STI panel (development funded via philanthropic partnership)
Development program for a multiplex panel to detect sexually transmitted infections (CT, NG, TV) intended for point-of-care and over-the-counter use; program supported by external grant funding.
Services
Technical support for product users via FAQ knowledgebase, support email, and phone lines; assistance with order inquiries and troubleshooting.
Commercial sales channels for point-of-care and enterprise deployments, including direct sales, partnerships, and ecommerce.
Collaboration with government agencies and philanthropic funders to develop and validate diagnostics, and to scale regulatory and commercial activities.
Technical support for product users via FAQ knowledgebase, support email, and phone lines; assistance with order inquiries and troubleshooting.
Commercial sales channels for point-of-care and enterprise deployments, including direct sales, partnerships, and ecommerce.
Collaboration with government agencies and philanthropic funders to develop and validate diagnostics, and to scale regulatory and commercial activities.
Expertise Areas
- Point-of-care and at-home molecular diagnostics
- Rapid PCR assay design and validation
- Multiplex assay development
- Regulatory submissions and compliance for diagnostics (EUA, 510(k), CLIA)
Key Technologies
- PCR-based molecular diagnostics
- Multiplex nucleic acid assays
- Saliva and nasal swab sample processing
- Portable diagnostic reader hardware
News & Updates
On February 24, 2025, Aptitude received FDA authorization for their COVID/Flu multiplex test.
On January 13, 2025, the platform was featured for its capabilities.
On January 6, 2025, the company announced funding to accelerate STI test development.
On March 21, 2024, the platform was featured for its innovative capabilities.
On January 3, 2024, the company announced a distribution partnership.
Launch of Metrix COVID-19 test on Amazon.
On October 1, 2023, the product was launched for sale on Amazon.
On February 24, 2025, Aptitude received FDA authorization for their COVID/Flu multiplex test.
On January 13, 2025, the platform was featured for its capabilities.
On January 6, 2025, the company announced funding to accelerate STI test development.
On March 21, 2024, the platform was featured for its innovative capabilities.
On January 3, 2024, the company announced a distribution partnership.
Launch of Metrix COVID-19 test on Amazon.
On October 1, 2023, the product was launched for sale on Amazon.